Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the ...

US clinical-stage biotech ArriVent BioPharma has entered into an exclusive license agreement with Shanghai-based Lepu ...

LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- The Global Antibody Drug Conjugate market was valued at USD 10.13 billion in 2023, growing at a CAGR of 14.37% during the forecast ...

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...